GFOR vs. ATHA, SNTI, CLDI, INAB, NKGN, FNCH, CHRO, AIM, APTO, and BCLI
Should you be buying Graf Acquisition Corp IV stock or one of its competitors? The main competitors of Graf Acquisition Corp IV include Athira Pharma (ATHA), Senti Biosciences (SNTI), Calidi Biotherapeutics (CLDI), IN8bio (INAB), NKGen Biotech (NKGN), Finch Therapeutics Group (FNCH), Chromocell Therapeutics (CHRO), AIM ImmunoTech (AIM), Aptose Biosciences (APTO), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry.
Graf Acquisition Corp IV vs.
Graf Acquisition Corp IV (NYSE:GFOR) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
Graf Acquisition Corp IV has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500.
Graf Acquisition Corp IV's return on equity of -2.50% beat Athira Pharma's return on equity.
28.5% of Graf Acquisition Corp IV shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 20.0% of Graf Acquisition Corp IV shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Athira Pharma has a consensus target price of $13.83, suggesting a potential upside of 2,490.51%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Graf Acquisition Corp IV.
Athira Pharma received 20 more outperform votes than Graf Acquisition Corp IV when rated by MarketBeat users.
In the previous week, Athira Pharma had 4 more articles in the media than Graf Acquisition Corp IV. MarketBeat recorded 4 mentions for Athira Pharma and 0 mentions for Graf Acquisition Corp IV. Athira Pharma's average media sentiment score of 0.96 beat Graf Acquisition Corp IV's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the news media.
Summary
Athira Pharma beats Graf Acquisition Corp IV on 7 of the 11 factors compared between the two stocks.
Get Graf Acquisition Corp IV News Delivered to You Automatically
Sign up to receive the latest news and ratings for GFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graf Acquisition Corp IV Competitors List
Related Companies and Tools
This page (NYSE:GFOR) was last updated on 1/31/2025 by MarketBeat.com Staff
Free GFOR Stock Alerts